bradloncar
$OPK licensing kallikrein prostate cancer Dx to IHT for UK, Sweden, Denmark. Geography makes sense since a lot of the R&D was done in Malmo.
- About
- Help
- Blog
- Jobs
- Press
- Tools
- Mobile
- Developers
- House Rules
- For Public Companies
- For Market Professionals
-
- Terms
- Privacy
- Disclaimer
- Market Quotes provided by Xignite © 2013 StockTwits, Inc.